OBJECTIVE To evaluate the effect of golimumab on physical function, health-related quality of life (HRQOL), and productivity in psoriatic arthritis (PsA). METHODS GO-REVEAL was a multicenter, randomized, placebo-controlled study. Adult patients with active PsA (n = 405) received golimumab (50 or 100 mg) or placebo every 4 weeks, with early escape at week 16 (placebo → 50 mg, 50 → 100 mg) or p...

Psoriasis, a chronic inflammatory skin disease, is caused by infiltrating lymphocytes and associated cytokines, including tumor necrosis factor (TNF)α, interleukin (IL)-6, and IL-17. Effective treatments, including pathogenesis-based biological agents against psoriasis, are currently under development. Although the role of reactive oxygen species (ROS) in the pathogenesis of psoriasis has been ...

Background: Psoriasis is a chronic disease with multiple biochemical and vascular abnormalities. Several studies have evaluated circulating levels of vascular endothelial growth factor (VEGF) in psoriasis, but none of them evaluated it after reaching a PASI-75 response, as a practical treatment goal. The aim of this study was to evaluate serum levels of VEGF in moderate to severe psoriatic pati...

Background There are many similarities with regard to contributing cytokines in patients with psoriasis and osteoporosis. A theory of probable relationship between these two entities has been proposed but there is no concordant consensus. The aim of this study was to evaluate bone mineral density (BMD) in patients with psoriasis. Method and materials This cross-sectional study of BMD was cond...

Although advantages of physiologically based pharmacokinetic models (PBPK) are now well established, PBPK models that are linked to pharmacodynamic (PD) models to predict pharmacokinetics (PK), PD, and efficacy of monoclonal antibodies (mAbs) in humans are uncommon. The aim of this study was to develop a PD model that could be linked to a physiologically based mechanistic FcRn model to predict ...

The Gulf Journal of Dermatology and Venereology ABSTRACT Background: Etanercept, a tumor necrosis factor antagonist, is an approved biologic agent for treatment of chronic plaque psoriasis in the United States and Europe. Objective: To observe the efficacy and safety profile of etanercept in patients with moderate to severe plaque psoriasis. Methods: In this retrospective study, 56 patients wer...

Psoriasis is a chronic relapsing disorder that involves the skin, nails and joints. With regard to the role of the immune system in psoriasis, the current study compared serum IgE concentration in patients with psoriasis with control group. Current case-control study was conducted in Dermatology clinic of Razi hospital, Tehran University of medical sciences, Tehran, Iran in 2012. Fifty-eight pa...

Introduction/Objective. The aim of this study was to evaluate psoriasis severity and psoriatic arthritis (PsA) as metabolic syndrome (MetS) insulin resistance (IR) predictors in patients with chronic plaque well if PsA are independent for IR regardless the MetS presence. Methods. This prospective, observational descriptive cross-sectional conducted at Dermatovenereological Clinic University Cli...

Introduction: Plantar psoriasis is a variant of and accounts for 3–4% total cases psoriasis. Psoriasis, an autoimmune chronic inflammatory disease the skin, can leave patient in agony with its distressing infection episodes. The homoeopathic system medicine offers wide range medicines that have beneficial role managing as depicted previous studies. Case summary: A distinct case plantar treated ...